Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

177 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21).
Leroy H, de Botton S, Grardel-Duflos N, Darre S, Leleu X, Roumier C, Morschhauser F, Lai JL, Bauters F, Fenaux P, Preudhomme C. Leroy H, et al. Among authors: de botton s. Leukemia. 2005 Mar;19(3):367-72. doi: 10.1038/sj.leu.2403627. Leukemia. 2005. PMID: 15674426 Clinical Trial.
Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial.
de Botton S, Chevret S, Coiteux V, Dombret H, Sanz M, San Miguel J, Caillot D, Vekhoff A, Gardembas M, Stamatoulas A, Conde E, Guerci A, Gardin C, Fey M, Cony Makhoul D, Reman O, de la Serna J, Lefrere F, Chomienne C, Degos L, Fenaux P; European APL group. de Botton S, et al. Among authors: de la serna j. Leukemia. 2003 Feb;17(2):339-42. doi: 10.1038/sj.leu.2402807. Leukemia. 2003. PMID: 12592333 Clinical Trial.
Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy.
de Botton S, Coiteux V, Chevret S, Rayon C, Vilmer E, Sanz M, de La Serna J, Philippe N, Baruchel A, Leverger G, Robert A, San Miguel J, Conde E, Sotto JJ, Bordessoule D, Fegueux N, Fey M, Parry A, Chomienne C, Degos L, Fenaux P. de Botton S, et al. Among authors: de la serna j. J Clin Oncol. 2004 Apr 15;22(8):1404-12. doi: 10.1200/JCO.2004.09.008. J Clin Oncol. 2004. PMID: 15084614 Clinical Trial.
Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.
de Botton S, Sanz MA, Chevret S, Dombret H, Martin G, Thomas X, Mediavilla JD, Recher C, Ades L, Quesnel B, Brault P, Fey M, Wandt H, Machover D, Guerci A, Maloisel F, Stoppa AM, Rayon C, Ribera JM, Chomienne C, Degos L, Fenaux P; European APL Group; PETHEMA Group. de Botton S, et al. Leukemia. 2006 Jan;20(1):35-41. doi: 10.1038/sj.leu.2404006. Leukemia. 2006. PMID: 16307026 Clinical Trial.
Prognostic value of minimal residual disease by real-time quantitative PCR in acute myeloid leukemia with CBFB-MYH11 rearrangement: the French experience.
Guièze R, Renneville A, Cayuela JM, Abdelali RB, Boissel N, de Botton S, Rubio MT, Mazingue F, Macintyre EA, Cheok M, Sigaux F, Fenaux P, Dombret H, Preudhomme C. Guièze R, et al. Among authors: de botton s. Leukemia. 2010 Jul;24(7):1386-8. doi: 10.1038/leu.2010.112. Epub 2010 May 27. Leukemia. 2010. PMID: 20508610 No abstract available.
Late first relapses in APL treated with all-trans-retinoic acid- and anthracycline- based chemotherapy: the European APL group experience (APL 91 and APL 93 trials).
Kelaidi C, Ades L, Chevret S, Sanz M, Guerci A, Thomas X, de Botton S, Raffoux E, Rayon C, Fegueux N, Bordessoule D, Rigal-Huguet F, Link H, Stoppa A, Vekhoff A, Meyer-Monard S, Castaigne S, Dombret H, Degos L, Fenaux P. Kelaidi C, et al. Among authors: de botton s. Leukemia. 2006 May;20(5):905-7. doi: 10.1038/sj.leu.2404158. Leukemia. 2006. PMID: 16541143 Clinical Trial. No abstract available.
Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the European group experience.
Ades L, Chevret S, De Botton S, Thomas X, Dombret H, Beve B, Sanz M, Guerci A, Miguel JS, Dela Serna J, Garo C, Stoppa AM, Reman O, Stamatoulas A, Fey M, Cahn JY, Sotto JJ, Bourhis JH, Parry A, Chomienne C, Degos L, Fenaux P; European APL Group. Ades L, et al. Among authors: de botton s. Leukemia. 2005 Feb;19(2):230-3. doi: 10.1038/sj.leu.2403597. Leukemia. 2005. PMID: 15565164 Clinical Trial.
Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group.
Callens C, Chevret S, Cayuela JM, Cassinat B, Raffoux E, de Botton S, Thomas X, Guerci A, Fegueux N, Pigneux A, Stoppa AM, Lamy T, Rigal-Huguet F, Vekhoff A, Meyer-Monard S, Ferrand A, Sanz M, Chomienne C, Fenaux P, Dombret H; European APL Group. Callens C, et al. Among authors: de botton s. Leukemia. 2005 Jul;19(7):1153-60. doi: 10.1038/sj.leu.2403790. Leukemia. 2005. PMID: 15889156
High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group.
Taksin AL, Legrand O, Raffoux E, de Revel T, Thomas X, Contentin N, Bouabdallah R, Pautas C, Turlure P, Reman O, Gardin C, Varet B, de Botton S, Pousset F, Farhat H, Chevret S, Dombret H, Castaigne S. Taksin AL, et al. Among authors: de botton s, de revel t. Leukemia. 2007 Jan;21(1):66-71. doi: 10.1038/sj.leu.2404434. Epub 2006 Oct 19. Leukemia. 2007. PMID: 17051246 Clinical Trial.
177 results